Abstract Number: 0107 • ACR Convergence 2023
Impact of Antiphospholipid Syndrome on Mortality of Hospitalized Ischemic Stroke Patients: A Retrospective Analysis of the National Inpatient Sample Database 2020
Background/Purpose: Antiphospholipid syndrome (APS) is recognized for its association with an elevated risk of ischemic strokes and other thromboembolic events. This study aims to compare…Abstract Number: 0178 • ACR Convergence 2023
Traditional and Lupus-Specific Risk Factors for Cardiovascular Events Among Patients with Systemic Lupus Erythematosus
Background/Purpose: Even among young women with systemic lupus erythematosus (SLE), accelerated atherosclerosis and coronary artery disease are common complications. Traditional risk scoring methods underestimate cardiovascular…Abstract Number: 0552 • ACR Convergence 2023
The Impact of Antiphospholipid Antibodies on Future Atherosclerotic Cardiovascular Disease Risk in Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) suffered from an increasing risk of cardiovascular diseases (23·3 events per 1000 patient-years). Antiphospholipid antibodies (aPLs), including anticardiolipin…Abstract Number: 0744 • ACR Convergence 2023
Personalizing Cardiovascular Risk Prediction for Patients with Systemic Lupus Erythematosus
Background/Purpose: Cardiovascular disease (CVD) risk is elevated in patients with SLE but underestimated by current general population prediction algorithms that do not include SLE-related variables.…Abstract Number: 1150 • ACR Convergence 2023
A Comparative Study of Cryofibrinogenemia Before and After COVID-19 Era
Background/Purpose: Cryofibrinogenemia (CF) is an under-recognized syndrome due to the lack of definitive criteria and the rarity of disease. CF may be primary (essential) or…Abstract Number: 1241 • ACR Convergence 2023
Adverse Childhood Experiences in a Paediatric Systemic Lupus Erythematosus Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, multiorgan autoimmune disease in which 20% of cases are diagnosed in childhood. Adverse childhood experiences (ACEs) are…Abstract Number: 1442 • ACR Convergence 2023
Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus
Background/Purpose: Awareness of comorbidity in patients with SLE is increasing. Most studies to date have described comorbidity burden in prevalent SLE. We estimated the incidence…Abstract Number: 2254 • ACR Convergence 2023
The Effects of Interleukin 17 Inhibitors on Major Adverse Cardiovascular Events in Patients Naïve to Biologic Agents with Psoriasis or Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Purpose: The aim of this systematic review is to determine the effects of IL-17 inhibitors on major adverse cardiovascular events (MACEs) in patients with psoriasis…Abstract Number: 2384 • ACR Convergence 2023
Major Cardiovascular Adverse Events in Patients with ANCA Vasculitis Compared with Hypertension Control Group
Background/Purpose: Vascular damage from inflammation in ANCA vasculitis leads to a sustained procoagulant state causing accelerated atherosclerosis. A population-based cohort study found that the risk…Abstract Number: 1195 • ACR Convergence 2022
Duloxetine and the Risk for Acute Myocardial Infarction and Stroke in Medicare Recipients with Non-Cancer Pain
Background/Purpose: Duloxetine is a serotonin-norepinephrine reuptake inhibitor antidepressant also prescribed for musculoskeletal and other forms of chronic pain. Its dual pharmacologic properties have the potential…Abstract Number: 1475 • ACR Convergence 2022
Epidemiology of Acute Ischemic Stroke in Patients with Systemic Lupus Erythematosus
Background/Purpose: Vascular events, including cerebrovascular accidents (CVA) occur earlier and more frequently in patients with Systemic Lupus Erythematosus (SLE) compared with healthy individuals. Several studies…Abstract Number: 0575 • ACR Convergence 2022
Myocardial Infarction and Stroke Risks Among Patients Who Initiated Treatment with Denosumab or Zoledronic Acid for Osteoporosis
Background/Purpose: There has been inconsistent evidence published regarding the cardio- and cerebrovascular benefits and risks of anti-osteoporosis medications. EU regulators requested Amgen to evaluate the…Abstract Number: 0446 • ACR Convergence 2021
Clinical Characteristics, Including History of Myocardial Infarction and Stroke, Among US PMO Women Initiating Treatment with Romosozumab and Other Anti-osteoporosis Therapies
Background/Purpose: This study is an ongoing USFDA post-marketing requirement (2020-2024) to assess the impact of boxed warning on romosozumab (romo) treatment and the feasibility of…Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…Abstract Number: 0409 • ACR Convergence 2020
Clinical Characteristics, Brain MRI Findings, and Diagnostic Approach of the Central Nervous System Vasculitis by Affected Vessel Size
Background/Purpose: Diagnosis of the central nervous system vasculitis (CNS-V) is made on the basis of image findings or brain biopsy. Recently, two different subtypes of…